Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
US Army
QuintilesIMS
Boehringer Ingelheim
Johnson and Johnson
Dow
Farmers Insurance
McKesson
Argus Health
Moodys

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,812,238

« Back to Dashboard

Which drugs does patent 6,812,238 protect, and when does it expire?

Patent 6,812,238 protects CRESEMBA and is included in two NDAs.

This patent has twenty-two patent family members in nineteen countries.
Summary for Patent: 6,812,238
Title: N-substituted carbamoyloxyalkyl-azolium derivatives
Abstract:N-substituted carbamoyloxyalkyl-azolium derivatives which have antifungal activity and are useful for the treatment of fungal diseases.
Inventor(s): Fukuda; Hiroshi (Tokyo, JP), Hayase; Tadakatsu (Chigasaki, JP), Mizuguchi; Eisaku (Kamakura, JP), Shimma; Nobuo (Chigasaki, JP), Ohwada; Jun (Kamakura, JP), Oikawa; Nobuhiro (Kawasaki, JP), Sakaitani; Masahiro (Chigasaki, JP), Tsukazaki; Masao (Fujisawa, JP), Umeda; Isao (Yokohama, JP)
Assignee: Basilea Pharmaceutica AG (Binningen, CH)
Application Number:09/702,944
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,812,238

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astellas CRESEMBA isavuconazonium sulfate POWDER;IV (INFUSION) 207501-001 Mar 6, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,812,238

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,151,182 Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives ➤ Subscribe
7,189,858 N-phenyl substituted carbamoyloxyalkyl-azolium derivatives ➤ Subscribe
7,459,561 N-substituted carbamoyloxyalkyl-azolium derivatives ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,812,238

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029403 ➤ Subscribe
Austria 291575 ➤ Subscribe
Australia 2835201 ➤ Subscribe
Australia 777859 ➤ Subscribe
Brazil 0015254 ➤ Subscribe
Brazil PI0015254 ➤ Subscribe
Canada 2388320 ➤ Subscribe
Canada 2680292 ➤ Subscribe
China 1185230 ➤ Subscribe
China 1387529 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
McKesson
Cipla
Johnson and Johnson
Colorcon
Baxter
Fish and Richardson
Covington
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot